



Att. Docket No. REG 710-A-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/009,852

Group: 1614

Filing Date: December 6, 2001

Examiner: Unknown

Title: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED
PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING
AND USING THEREOF

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernadette B. Fahey
Bernadette B. Fahey

January 28, 2003
Date

January 28, 2003

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Assistant Comm. Patent and Trademarks
Box Information Disclosure Statement
Washington, D.C. 20231

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- [x] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office

action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

- [] (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

[] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contained in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

- [] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- [] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

[] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contained in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

[] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

REQUEST FOR TRANSFER OF REFERENCE COPIES

[] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN _____, filed _____, be transferred to the subject application for consideration by the Examiner

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$_____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted

Linda O. Palladino

Linda O. Palladino

Reg. No. 45,636

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/009,853

Applicant: Papadopoulos, et al.

Date Filed: December 6, 2001

Title: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING AND USING THEREOF

Examiner: Unknown

Group Art Unit: 1614

January 28, 2003

U.S. PATENT DOCUMENTS

Examiner <u>Initials</u>	Patent <u>Number</u>	Issue <u>Date</u>	Publication <u>Number</u>	Publication <u>Date</u>	<u>Name</u>
-----------------------------	-------------------------	----------------------	------------------------------	----------------------------	-------------

FOREIGN PATENT DOCUMENTS

Examiner <u>Initials</u>	Document <u>Number</u>	<u>Date</u>	<u>Country</u>	Class/ <u>Date Subclass</u>	Translation <u>Yes</u> <u>No</u>
-----------------------------	---------------------------	-------------	----------------	--------------------------------	-------------------------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

_____ Davis-Smyth, T., et al., 1996, "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade", The EMBO Journal 15(18):4919-4927.


EXAMINER
CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.



Respectfully submitted,

By:

Linda O. Palladino

Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400